LONDON: Britain’s GlaxoSmithKline has asked its shareholders to vote at a meeting on Dec 18 on its proposed major deal with Switzerland’s Novartis, which will see the two pharmaceutical group trade more than $20 billion of assets.

The transaction, which includes GSK buying Novartis’ vaccines business, Novartis purchasing GSK’s cancer drugs, and the two groups tying up in consumer healthcare, was unveiled in April.

In a letter to shareholders endorsing the deal, GSK’s chairman Christopher Gent said approval would strengthen its franchises in vaccines and consumer healthcare to complement its leading position in respiratory and HIV.

“This is the most significant transaction for the Company since the creation of GlaxoSmithKline in 2000,” he said.

Published in Dawn, November 25th , 2014

Opinion

Editorial

‘Source of terror’
Updated 29 Mar, 2024

‘Source of terror’

It is clear that going after militant groups inside Afghanistan unilaterally presents its own set of difficulties.
Chipping in
29 Mar, 2024

Chipping in

FEDERAL infrastructure development schemes are located in the provinces. Most such projects — for instance,...
Toxic emitters
29 Mar, 2024

Toxic emitters

IT is concerning to note that dozens of industries have been violating environmental laws in and around Islamabad....
Judiciary’s SOS
Updated 28 Mar, 2024

Judiciary’s SOS

The ball is now in CJP Isa’s court, and he will feel pressure to take action.
Data protection
28 Mar, 2024

Data protection

WHAT do we want? Data protection laws. When do we want them? Immediately. Without delay, if we are to prevent ...
Selling humans
28 Mar, 2024

Selling humans

HUMAN traders feed off economic distress; they peddle promises of a better life to the impoverished who, mired in...